APA (7th ed.) Citation

FC, S., JL, K., A, M., J, N., F, W., A, N., . . . A, C. (2021). Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS medicine, 18(12), e1003875. https://doi.org/10.1371/journal.pmed.1003875

Chicago Style (17th ed.) Citation

FC, Semitala, et al. "Completion of Isoniazid-rifapentine (3HP) for Tuberculosis Prevention Among People Living with HIV: Interim Analysis of a Hybrid Type 3 Effectiveness-implementation Randomized Trial." PLoS Medicine 18, no. 12 (2021): e1003875. https://doi.org/10.1371/journal.pmed.1003875.

MLA (9th ed.) Citation

FC, Semitala, et al. "Completion of Isoniazid-rifapentine (3HP) for Tuberculosis Prevention Among People Living with HIV: Interim Analysis of a Hybrid Type 3 Effectiveness-implementation Randomized Trial." PLoS Medicine, vol. 18, no. 12, 2021, p. e1003875, https://doi.org/10.1371/journal.pmed.1003875.